2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Jennifer L. Atlas, MD, discusses the current cutaneous squamous cell carcinoma treatment paradigm.
Jennifer L. Atlas, MD, a medical oncologist specializing in lung cancer at Levine Cancer Institute, Carolinas HealthCare System/Atrium Health, discusses the current cutaneous squamous cell carcinoma (CSCC) treatment paradigm.
The standard of care for patients with locally advanced CSCC is surgical resection, says Atlas.
The majority of patients with low-risk CSCC will undergo surgical resection, Atlas explains. However, whether systemic therapies provide additional benefit to surgical resection is not well defined.
However, in situations where the disease cannot be fully resected or the patient is considered to be at high risk for surgery, systemic therapies such as cemiplimab-rwlc (Libtayo) should be considered, Atlas concludes.